AccuFusion™ RNA Lung Cancer Panel for targeted gene fusion detection and research via amplicon-based target enrichment for Next Generation Sequencing (NGS) on Illumina sequencing platforms
AccuFusion RNA Lung Cancer Panel for next-generation sequencing enables detection of 280 gene fusions associated with non-small cell lung cancer. In contrast to the OmniFusionTM panels, AccuFusion workflow is for targeted and focused detection of known fusion partners. The AccuFusion dual-primer based amplification technology uses expertly designed and target specific primers to generate libraries without fragmentation of the input material. Compared to other methods such as qPCR, FISH, or Sanger sequencing, Paragon Genomics targeted fusion sequencing method allows robust multiplexed detection of variants using minimum sample input and a simple workflow (Figure 1).
The chemistry allows sensitive detection of rare variants with using as little as 10ng RNA input. The panel was also designed to be compatible with degraded FFPE samples for improved performance, even under less than ideal sample conditions.
Learn more about the technology on our Fusion Technology page.
- Targeted identification of RNA fusions associated with lung cancer
Interrogate ~280 known RNA fusions using a target specific dual-primer multiplex PCR method.
- Fast, streamlined workflow
Generate sequencing-ready libraries in just 6 hours using a rapid, four-step protocol from extracted RNA to sequence ready libraries.
- Excellent performance with high on-target rate
Prepare high-quality targeted NGS libraries using AccuFusion RNA Fusion Technology to achieve high on-target rate for efficient sequencing
- Sensitive Detection
Can detect down to 1% variant frequency with high confidence.
Store at -20 °C.
For Research Use Only. Not for use in diagnostic procedures.